PD-L1 in Tumor-derived EVs impacts immune evasion by targeting PD-1 on CD8+ T cells, leading to immunosuppression and resistance to PD-1/PD-L1 checkpoint therapies (90). The gene discussed is CD8A; the disease is neoplasm.